The Reasons Why I Believe XERS is Undervalued

“The stock market is filled with individuals who know the price of everything but the value of nothing” — Phillip Fisher

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. As of writing this article, XERS is trading at $5.12.

  1. Shorts…

Goutham Lali

Venture Scout at Mountside Ventures | LSE Accounting & Finance | Bridging the gap between Family Offices and disruptive tech investments

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store